Actinium Pharmaceuticals, Inc. Stock Deutsche Boerse AG
Stocks
7AY1
US00507W2061
Biotechnology & Medical Research
|
Real-time Estimate
Tradegate
01:58:03 01/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 1.032 EUR | +1.98% |
|
-1.60% | -16.33% |
| 08-15 | Actinium Pharmaceuticals Expands Manufacturing Capacity for Actimab-A Program | CI |
| 08-15 | Actinium Pharmaceuticals, Inc. Amends Its Investigational New Drug | CI |
| Market Cap | 35.84M 31.56M 29.91M 27M 50.88M 3.44B 51.54M 358M 138M 1.76B 135M 132M 5.63B | P/E 2026 * |
6.45x | P/E 2027 * | -1.7x |
|---|---|---|---|---|---|
| Enterprise Value | 35.84M 31.56M 29.91M 27M 50.88M 3.44B 51.54M 358M 138M 1.76B 135M 132M 5.63B | EV / Sales 2026 * |
2.05x | EV / Sales 2027 * | - |
| Free-Float |
90.17% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| ATNM | Delayed | |
Tradegate
| 7AY1 | Real-time | |
|
CBOE
| ATNM | Real-time | |
|
Deutsche Boerse AG
| 7AY1 | Delayed | |
|
Börse Stuttgart
| 7AY1 | Delayed | |
|
Boerse Muenchen
| 7AY1 | Real-time |
| 1 day | +1.98% | ||
| 1 week | -1.60% | ||
| Current month | +15.76% | ||
| 1 month | +15.76% | ||
| 3 months | +15.90% | ||
| 6 months | +10.50% | ||
| Current year | -16.33% |
| 1 week | 0.98 |  | 1.02 |
| 1 month | 0.84 | | 1.18 |
| Current year | 0.63 | | 1.25 |
| 1 year | 0.63 | | 1.43 |
| 3 years | 0.63 | | 9.8 |
| 5 years | 0.63 | | 19.8 |
| 10 years | 0.63 | | 46.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sandesh Seth
CEO | Chief Executive Officer | 62 | 09/06/2017 |
Steffen Heeger
CTO | Chief Tech/Sci/R&D Officer | - | 01/06/2026 |
Adeela Kamal
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
C. Nicholson
BRD | Director/Board Member | 71 | 01/01/2008 |
Sandesh Seth
CHM | Chairman | 62 | 01/10/2013 |
| Director/Board Member | 68 | 08/11/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.98% | -1.60% | - | - | 35.84M | |
| +4.16% | -0.30% | +58.96% | +94.17% | 71.53B | |
| -0.19% | +1.32% | +37.20% | +81.33% | 60.12B | |
| -1.51% | +2.39% | +9.10% | +36.79% | 48.85B | |
| +0.67% | +0.98% | +42.40% | +39.51% | 44.28B | |
| +1.16% | +8.45% | +342.96% | +690.45% | 43.83B | |
| +1.42% | +1.54% | +8.78% | +107.62% | 41.53B | |
| -0.67% | -0.45% | +4.47% | +46.37% | 30.13B | |
| +4.77% | +6.46% | +41.54% | +22.78% | 27.98B | |
| +0.30% | -2.20% | -19.63% | +356.21% | 25.25B | |
| Average | +1.23% | +0.48% | +58.42% | +163.91% | 43.72B | |
| Weighted average by Cap. | +1.23% | +0.63% | +63.46% | +154.85% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 17.5M 15.41M 14.6M 13.18M 24.84M 1.68B 25.16M 175M 67.23M 858M 65.71M 64.28M 2.75B | - |
| Net income | 5.91M 5.21M 4.93M 4.45M 8.39M 567M 8.5M 59.01M 22.71M 290M 22.2M 21.71M 929M | -30.95M -27.25M -25.82M -23.31M -43.93M -2.97B -44.5M -309M -119M -1.52B -116M -114M -4.86B |
| Net Debt | - | - |
| Date | Price | Change |
|---|---|---|
| 30/09/26 | €0.9840 | -2.77% |
| 29/09/26 | €1.012 | -1.17% |
| 28/09/26 | €1.024 | +0.20% |
| 25/09/26 | €1.022 | +1.19% |
| 24/09/26 | €1.010 | +1.00% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATNM Stock
- 7AY1 Stock
Select your edition
All financial news and data tailored to specific country editions
